BORA PHARMACEUTICALS LTD (6472) - Net Assets
Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) has net assets worth NT$16.63 Billion TWD (≈ $523.89 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$45.33 Billion ≈ $1.43 Billion USD) and total liabilities (NT$28.70 Billion ≈ $904.30 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 6472 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$16.63 Billion |
| % of Total Assets | 36.68% |
| Annual Growth Rate | 48.12% |
| 5-Year Change | 454.23% |
| 10-Year Change | N/A |
| Growth Volatility | 37.61 |
BORA PHARMACEUTICALS LTD - Net Assets Trend (2019–2025)
This chart illustrates how BORA PHARMACEUTICALS LTD's net assets have evolved over time, based on quarterly financial data. See 6472 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BORA PHARMACEUTICALS LTD (2019–2025)
The table below shows the annual net assets of BORA PHARMACEUTICALS LTD from 2019 to 2025. For live valuation and market cap data, see 6472 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | NT$17.47 Billion ≈ $550.47 Million |
+16.39% |
| 2024-09-30 | NT$15.01 Billion ≈ $472.95 Million |
+27.59% |
| 2023-09-30 | NT$11.77 Billion ≈ $370.69 Million |
+128.89% |
| 2022-09-30 | NT$5.14 Billion ≈ $161.95 Million |
+63.06% |
| 2021-09-30 | NT$3.15 Billion ≈ $99.32 Million |
+27.90% |
| 2020-09-30 | NT$2.46 Billion ≈ $77.65 Million |
+49.04% |
| 2019-09-30 | NT$1.65 Billion ≈ $52.10 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BORA PHARMACEUTICALS LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1167.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$7.49 Billion | 48.67% |
| Common Stock | NT$1.27 Billion | 8.28% |
| Other Comprehensive Income | NT$4.11 Billion | 26.72% |
| Other Components | NT$2.51 Billion | 16.33% |
| Total Equity | NT$15.38 Billion | 100.00% |
BORA PHARMACEUTICALS LTD Competitors by Market Cap
The table below lists competitors of BORA PHARMACEUTICALS LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Huizhou China Eagle Electronic Technology Co Ltd
SHE:002579
|
$1.66 Billion |
|
U-Ming Marine Transport Corp
TW:2606
|
$1.66 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
$1.66 Billion |
|
Dongfeng Automobile Co Ltd
SHG:600006
|
$1.66 Billion |
|
Fine Organic Industries Limited
NSE:FINEORG
|
$1.65 Billion |
|
Suning Commerce Group Co Ltd
SHE:002024
|
$1.65 Billion |
|
PLUXEE NV
PA:PLX
|
$1.65 Billion |
|
Shenzhen Hepalink Pharmaceutical Co Ltd
SHE:002399
|
$1.65 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BORA PHARMACEUTICALS LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,867,402,000 to 15,381,399,000, a change of 2,513,997,000 (19.5%).
- Net income of 2,981,311,000 contributed positively to equity growth.
- Dividend payments of 1,448,922,000 reduced retained earnings.
- Share repurchases of 99,884,000 reduced equity.
- New share issuances of 127,554,000 increased equity.
- Other comprehensive income increased equity by 3,745,716,000.
- Other factors decreased equity by 2,791,778,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$2.98 Billion | +19.38% |
| Dividends Paid | NT$1.45 Billion | -9.42% |
| Share Repurchases | NT$99.88 Million | -0.65% |
| Share Issuances | NT$127.55 Million | +0.83% |
| Other Comprehensive Income | NT$3.75 Billion | +24.35% |
| Other Changes | NT$-2.79 Billion | -18.15% |
| Total Change | NT$- | 19.54% |
Book Value vs Market Value Analysis
This analysis compares BORA PHARMACEUTICALS LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.64x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 26.83x to 3.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | NT$15.37 | NT$412.50 | x |
| 2020-09-30 | NT$21.30 | NT$412.50 | x |
| 2021-09-30 | NT$33.67 | NT$412.50 | x |
| 2022-09-30 | NT$38.27 | NT$412.50 | x |
| 2023-09-30 | NT$73.17 | NT$412.50 | x |
| 2024-09-30 | NT$102.38 | NT$412.50 | x |
| 2025-09-30 | NT$113.32 | NT$412.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BORA PHARMACEUTICALS LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.38%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.68%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 2.91x
- Recent ROE (19.38%) is below the historical average (25.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 18.44% | 19.95% | 0.45x | 2.05x | NT$139.66 Million |
| 2020 | 23.47% | 32.14% | 0.26x | 2.84x | NT$331.95 Million |
| 2021 | 23.78% | 15.30% | 0.66x | 2.34x | NT$434.48 Million |
| 2022 | 30.74% | 13.26% | 0.46x | 5.03x | NT$939.08 Million |
| 2023 | 33.35% | 21.34% | 0.57x | 2.76x | NT$2.12 Billion |
| 2024 | 30.61% | 20.47% | 0.42x | 3.54x | NT$2.65 Billion |
| 2025 | 19.38% | 15.68% | 0.43x | 2.91x | NT$1.44 Billion |
Industry Comparison
This section compares BORA PHARMACEUTICALS LTD's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,032,347,900
- Average return on equity (ROE) among peers: 4.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BORA PHARMACEUTICALS LTD (6472) | NT$16.63 Billion | 18.44% | 1.73x | $1.66 Billion |
| Grape King Bio Ltd (1707) | $1.74 Billion | 9.43% | 0.48x | $465.31 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $3.12 Billion | 7.90% | 0.56x | $352.99 Million |
| Maywufa Co Ltd (1731) | $1.47 Billion | 5.23% | 0.78x | $91.29 Million |
| ScinoPharm Taiwan Ltd (1789) | $8.56 Billion | 11.21% | 0.11x | $528.15 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $1.49 Billion | 0.80% | 0.34x | $1.60 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $44.08 Million |
| LIWANLI Innovation Co Ltd (3054) | $1.51 Billion | 4.15% | 0.15x | $172.28 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $480.02 Million |
| TTY Biopharm Co Ltd (4105) | $5.77 Billion | 14.42% | 0.61x | $577.35 Million |
| Phytohealth Corp (4108) | $1.56 Billion | -10.88% | 0.06x | $75.09 Million |
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more